Cover Image
Market Research Report

Biopharmaceutical Contract Manufacturing Market (3rd Edition), 2019 - 2030

Published by ROOTS ANALYSIS Product code 329397
Published Content info 850 Pages
Delivery time: 1-2 business days
Price
Back to Top
Biopharmaceutical Contract Manufacturing Market (3rd Edition), 2019 - 2030
Published: April 1, 2019 Content info: 850 Pages
Description

Overview:

Over the years, the biopharmaceutical market has grown into a prominent and promising segment of the overall pharmaceutical industry. Characterized by a number of blockbuster therapies (Humira, Rituxan, Lantus, Avastin, Herceptin and Remicade ) and a robust pipeline of product / therapy candidates, the market is poised for significant growth in the coming years. It is worth mentioning that much of the anticipated success of the biopharmaceutical market is dependent on new biologics currently under development and biosimilars. The impending growth also indicates the rising importance of manufacturing capacity within the industry. The costs associated with acquiring manufacturing capabilities are exorbitant and, therefore, it is difficult for companies with limited finances and capacity constraints to succeed by themselves. These constraints have led many of the smaller players in the industry and, at times, certain pharma giants as well, to outsource a significant part of their business operations to contract service providers. Contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) are known to offer significant cost-benefits, access to larger production capacities and reductions in time-to-market.

“The development pipelines of big biopharma companies are extensive and it is difficult for such players to carry out manufacturing operations using in house capacities. As a result, such companies often opt to outsource certain aspects of their production processes, predominantly drug substance manufacturing and aseptic filling. Therefore, there is a high demand for contract services from the aforementioned companies.” - Senior Manager Strategic Marketing, a Germany-based Large sized CMO.

Owing to the growing number of start-ups that are engaged in R&D of novel biologics, there is significant opportunity for the CMOs in this domain. It is worth highlighting that, since 2000, more than115 new CMOs have been established in order to cater to the growing demand for novel biologics that have specific manufacturing requirements. The contemporary contract services market features a mix of large and small-sized CMOs and is characterized by multiple mergers and acquisitions as stakeholders strive to broaden their respective service portfolios. This has enabled several CMOs to offer end-to-end services, ranging from drug development, including preliminary R&D, preclinical and clinical trials, to commercial scale production and regulatory filings. Despite the fact that the biopharmaceutical sector is amongst the most highly regulated industries, we expect the demand for core competencies to continue to drive sponsor companies to outsource various parts of their product development and manufacturing operations. Amidst tough competition, the availability of advanced tools and technologies is an important differentiating factor and is likely to grant a competitive edge to certain CMOs over other stakeholders.

Scope of the Report:

The “Biopharmaceutical Contract Manufacturing Market (3rd edition), 2019 - 2030” report features an extensive study on the contract service providers within the biopharmaceutical industry. The study features in-depth analysis, highlighting the capabilities of a diverse set of biopharmaceutical CMOs and CDMOs. Amongst other elements, the report includes:

  • A detailed review of the overall landscape of the biopharmaceutical contract manufacturing market, featuring a comprehensive list of active CMOs and detailed analysis of the manufacturing service providers based on a number of parameters, such as scale of operation (preclinical, clinical and commercial), type of biologics manufactured (peptides / proteins, antibodies, vaccines, cell therapies, gene therapies, antibody drug conjugates, vectors, biosimilars, nucleic acids and others), type of expression systems used (mammalian, microbial and others), year of establishment, employee size, geographical location of the CMO, number of manufacturing facilities, as well as the location of these facilities, GMP compliance, affiliations to regulatory agencies, type of bioreactors used (single-use bioreactors and stainless steel bioreactors), mode of operation of bioreactors (batch, fed-batch and perfusion) and bioprocessing capacity.
  • Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing and packaging of biologics. Each profile provides an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, and details on partnerships, recent developments (expansions), as well as a comprehensive future outlook.
  • A detailed discussion on the key enablers in this domain, including certain niche product classes, such as antibody drug conjugates (ADCs), bispecific antibodies, cell therapies, gene therapies and viral vectors, which are likely to have a significant impact on the growth of the contract services market.
  • A case study on the growing global biosimilars market, highlighting the opportunities for biopharmaceutical CMOs and CDMOs.
  • A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.
  • A discussion on challenges related to in-house manufacturing, featuring a brief overview of the various parameters that a drug / therapy developer may need to take into consideration while deciding whether to manufacture its products in-house or outsource.
  • An analysis of the recent collaborations (signed since 2013) focused on the contract manufacturing of biologics; the analysis is based on various parameters, such as the year in which the agreement was signed, type of agreement, focus area and type of biologics.
  • A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2013-2018, along with the geographical distribution of this activity. The analysis also depicts the relationship between important deal multiples based on the revenue, number of employees and experience of the acquired company.
  • An analysis on the recent trends within biopharmaceutical contract manufacturing industry, highlighting various facility and capability expansions. In addition, it provides information on the technology advancements related to biomanufacturing.
  • A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders (small-sized, mid-sized, large and very large CMOs / CDMOs) in the market, using data from both secondary and primary research. The study examines the distribution of global biopharmaceutical manufacturing capacity by scale of operation (preclinical / clinical, commercial), size of company (small-sized, mid-sized, large and very large), and geography (North America (the US and Canada), Europe (Italy, Germany, France, Spain, the UK and rest of Europe), Asia and Middle East (China, India, Japan, South Korea and rest of the Asia and Middle East), and rest of the world (including Australia).
  • An informed estimate of the annual demand for biologics, taking into account the top 20 biologics, based on a various relevant parameters, such as target patient population, dosing frequency and dose strength of the abovementioned products.
  • A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry's evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall pharmaceutical industry.
  • A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing CMO services to medical device developers.
  • One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as growth of the overall biopharmaceutical market, cost of goods sold, and direct manufacturing costs, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and mid to long term, for the period 2019-2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] commonly outsourced business operations (active pharmaceutical ingredients (APIs) and finished dosage formulations (FDFs)), [B] types of expression systems (mammalian, microbial and others), [C] size of the company (small-sized, mid-sized and large / very large), [D] scale of operation (preclinical, clinical and commercial) and [E] key geographical regions (North America (US, Canada), Europe (UK, France, Germany, Italy and Spain), Asia (China and India) and rest of the world (Australia)). To account for the uncertainties associated with the manufacturing of biopharmaceuticals and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Astrid Brammer, Senior Manager Business Development, Richter-Helm
  • Birgit Schwab, Senior Manager Strategic Marketing, Rentschler Biotechnologie
  • Christian Bailly, Director of CDMO, Pierre Fabre
  • Claire Otjes, Assistant Marketing Manager, Batavia Biosciences
  • David C Cunningham, Director Corporate Development, Goodwin Biotechnology
  • Dietmar Katinger, Chief Executive Officer, Polymun Scientific
  • Denis Angioletti, Chief Commercial Officer, Cerbios-Pharma
  • Jeffrey Hung, Chief Commercial Officer, Vigene Biosciences
  • Kevin Daley, Director Pharmaceuticals, Novasep
  • Mark Wright, Site Head, Grangemouth, Piramal Healthcare
  • Nicolas Grandchamp, R&D Leader, GEG Tech
  • Raquel Fortunato, Chief Executive Officer, GenIbet Biopharmaceuticals
  • Sebastian Schuck, Head of Business Development, Wacker Biotech
  • Stephen Taylor, Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies
  • Tatjana Buchholz, Marketing Manager, PlasmidFactory and Marco Schmeer, Project Manager, PlasmidFactory
  • TiTim Oldham, Chief Executive Officer, Cell Therapies

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Example Insights:

Chapter Outlines:

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the likely evolution of the biopharmaceutical contract manufacturing market in the mid to long term.

Chapter 3 provides a general introduction to biopharmaceuticals and biopharmaceutical manufacturing processes. The chapter also includes an overview of the various expression systems used for the development of different types of biotherapeutic products. It features a brief overview of contract manufacturing and includes a detailed discussion on the need for outsourcing within the biopharmaceutical industry. In this chapter, we have presented a list of commonly outsourced biomanufacturing activities; the chapter concludes with a discussion on the challenges that are currently associated within the market.

Chapter 4 provides a comprehensive overview of the global biopharmaceutical contract manufacturing landscape. It includes information related to over 240 CMOs that are currently active in this domain. In addition, it features an in-depth analysis of the market, based on a number of parameters, such as scale of operation, type of biologics manufactured and type of expression systems being utilized. Further, it contains details on the year of establishment, employee size, geographical location of the CMO, number of manufacturing facilities, as well as location of these facilities, GMP compliance, affiliations to regulatory agencies. Moreover, the chapter provides information on the production capabilities of CMOs, based on type of bioreactor, mode of operation of bioreactors and bioreactor capacity.

Chapter 5 features detailed profiles of some of the key players that are active in the biopharmaceutical contract manufacturing market in the US. Each profile presents a brief overview of the company, its contract service offerings, financial information (if available), manufacturing capabilities and facilities, partnerships, recent developments, and awards and accolades received.

Chapter 6 features detailed profiles of some of the key players that are active in the biopharmaceutical contract manufacturing market in Europe. Each profile presents a brief overview of the company, its contract service offerings, financial information (if available), manufacturing capabilities and facilities, partnerships, recent developments, and awards and accolades received.

Chapter 7 features detailed profiles of some of the key players that are active in the biopharmaceutical contract manufacturing market in Asia and other regions of the world. Each profile presents a brief overview of the company, its contract service offerings, financial information (if available), manufacturing capabilities and facilities, partnerships, recent developments, and awards and accolades received.

Chapter 8 focuses on the key enablers in this domain, including certain niche product classes, such as ADCs, bispecific antibodies, cell therapies, gene therapies and viral vectors, which are likely to have a significant impact on the growth of the contract services market. The chapter provides detailed a market overview, including information on the pipeline, and the presence of CMOs in each of the aforementioned segments.

Chapter 9 is a case study focused on outsourcing of operations related to biosimilars, which represents a major growth opportunity for biopharmaceutical CMOs. It provides an overview of biosimilars and captures information on the various CMOs that are actively involved in this segment of the biopharmaceutical market.

Chapter 10 is a case study comparing the key characteristics of large and small molecule drugs, along with information on the steps involved in their respective manufacturing processes.

Chapter 11 is a case study focused on challenges associated with in-house manufacturing. It also provides details on the outsourcing trends in this domain, along with information related to various partnership models that are being used by various stakeholders to partner with CMOs. In addition, it features a list of recently approved biologics, with information on the type of biologic, target indication(s), developer and manufacturing approach adopted by the developer. Further, the chapter features a brief overview of the various parameters that a drug / therapy developer may need to take into consideration while deciding whether to manufacture its products in-house or outsource.

Chapter 12 features an elaborate analysis and discussion of the various collaborations and partnerships that have been inked amongst players since 2013. It includes a brief description on the various types of partnership models (which include product-based agreements, process-based agreements, licensing agreements, co-service agreements / ventures, R&D agreements and other outsourcing service agreements) that have been adopted by stakeholders in this domain. It also consists of a schematic representation showcasing the players that have established the maximum number of alliances related to the manufacturing of cell-based therapies. Furthermore, we have provided a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents. In addition, the chapter includes a detailed analysis of the mergers and acquisitions that have taken place in this space, highlighting the trend in the number of companies acquired from 2012-2018. The analysis also provides information on the key value drivers for these mergers and acquisitions and the corresponding acquisition deal multiples.

Chapter 13 presents an analysis of the recent developments in the biopharmaceutical contract manufacturing market. It provides an overview of other market trends, such as investments and facility expansions. In addition, it provides details on the emerging technologies related to biomanufacturing processes.

Chapter 14 features a comprehensive analysis of the global / regional capacity of contract manufacturers that are engaged in the manufacturing of biopharmaceutical products. The analysis takes into consideration the individual development and manufacturing capacities of various stakeholders (small-sized, mid-sized, large and very large CMOs / CDMOs) in the market, using data from both secondary and primary research. The study examines the distribution of global biopharmaceutical manufacturing capacity by scale of operation (preclinical / clinical, commercial), size of the company (small-sized, mid-sized, large and very large), region of operation (North America (the US and Canada), Europe (Italy, Germany, France, Spain, the UK and rest of Europe), Asia and Middle East (China, India, Japan, South Korea and rest of the Asia and Middle East), and rest of the world(including Australia).

Chapter 15 features a comprehensive analysis of the annual demand of biotherapeutics (in grams), taking into account the top 20 biologics, based on a various relevant parameters, such as target patient population, dosing frequency and dose strength of the abovementioned products.

Chapter 16 presents a comprehensive market forecast analysis, highlighting the likely growth of the biologics manufacturing market till the year 2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] commonly outsourced business operations (active pharmaceutical ingredients (APIs) and finished dosage formulations (FDFs)), [B] types of expression systems (mammalian, microbial and others), [C] size of the company (small-sized, mid-sized and large / very large), [D] scale of operation (preclinical, clinical and commercial) and [E] key geographical regions (North America (US, Canada), Europe (UK, France, Germany, Italy and Spain), Asia (China and India) and rest of the world (Australia)).

Chapter 17 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of biopharmaceuticals manufacturing market, under a comprehensive SWOT framework.

Chapter 18 is a summary of the entire report. It provides the key takeaways and presents our independent opinion of the biopharmaceutical CMOs market, based on the research and analysis described in the previous chapters. It also provides a recap of some of the upcoming future trends, which, we believe, are likely to influence the growth of biopharmaceutical CMOs.

Chapter 19 presents insights from the survey conducted for this study. The participants, who were primarily Director / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their services and the associated commercial potential.

Chapter 20 contains the transcripts of interviews conducted with representatives from renowned organizations that are engaged in the biopharmaceutical contract manufacturing domain. In this study, we spoke to Astrid Brammer (Senior Manager Business Development, Richter-Helm), Birgit Schwab (Senior Manager Strategic Marketing, Rentschler Biotechnologie), Christian Bailly (Director of CDMO, Pierre Fabre), Claire Otjes (Assistant Marketing Manager, Batavia Biosciences), David C Cunningham (Director Corporate Development, Goodwin Biotechnology), Dietmar Katinger (Chief Executive Officer, Polymun Scientific), Denis Angioletti (Chief Commercial Officer, Cerbios-Pharma), Jeffrey Hung (Chief Commercial Officer, Vigene Biosciences), Kevin Daley (Director Pharmaceuticals, Novasep), Mark Wright (Site Head, Grangemouth, Piramal Healthcare), Nicolas Grandchamp (R&D Leader, GEG Tech), Raquel Fortunato (Chief Executive Officer, GenIbet Biopharmaceuticals), Sebastian Schuck (Head of Business Development, Wacker Biotech), Stephen Taylor (Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies), Tatjana Buchholz (Marketing Manager, PlasmidFactory) and Marco Schmeer (Project Manager, PlasmidFactory) and Tim Oldham (Chief Executive Officer, Cell Therapies).

Chapter 21 is an appendix that contains the list of non-industry players that offer contract services for biologics.

Chapter 22 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 23 is an appendix that provides the list of companies and organizations mentioned in the report.

Table of Contents
Product Code: RA100132

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Context and Background
  • 3.2. An Overview of Biopharmaceuticals
  • 3.3. Biopharmaceutical Manufacturing
    • 3.3.1. Types of Expression Systems
      • 3.3.1.1. Bacterial Expression Systems
      • 3.3.1.2. Yeast Expression Systems
      • 3.3.1.3. Fungal Expression Systems
      • 3.3.1.4. Insect Expression Systems
      • 3.3.1.5. Plant Expression Systems
      • 3.3.1.6. Mammalian Expression Systems
    • 3.3.2. Processing Steps
      • 3.3.2.1. Upstream Processing
      • 3.3.2.2. Downstream Processing
  • 3.4. An Overview of Contract Manufacturing
  • 3.5. Need for Outsourcing in the Biopharmaceutical Industry
  • 3.6. Commonly Outsourced Operations in the Biopharmaceutical Industry
  • 3.7. Basic Guidelines for Selecting a CMO Partner
  • 3.8. Advantages of Outsourcing Manufacturing Services
  • 3.9. Risks and Challenges Associated with Biopharmaceutical Contract Manufacturing
  • 3.10. Future Perspectives

4. COMPETITIVE LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Biopharmaceutical Contract Manufacturers: Overall Market Landscape
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Size of Employee Base
    • 4.2.3. Analysis by Location of Headquarters
    • 4.2.4. Analysis by Location of Manufacturing Facilities
    • 4.2.5. Analysis by Type of Biologics Manufactured
    • 4.2.6. Analysis by Scale of Operation
    • 4.2.7. Analysis by Expression Systems
    • 4.2.8. Analysis by Type of Bioreactor and Mode of Operation
    • 4.2.9. Analysis by Biomanufacturing Capacity
    • 4.2.10. Analysis by Packaging Form

5. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN NORTH AMERICA

  • 5.1. Chapter Overview
  • 5.2. Biopharmaceutical Outsourcing in the US: Regulatory Scenario
  • 5.3. Leading Biopharma CMOs in North America
    • 5.3.1. AMRI (OsoBio)
      • 5.3.1.1. Company Overview
      • 5.3.1.2. Services Portfolio
      • 5.3.1.3. Biomanufacturing Services
      • 5.3.1.4. Financial Information
      • 5.3.1.5. Manufacturing facilities
      • 5.3.1.6. Partnerships
      • 5.3.1.7. Recent Developments
      • 5.3.1.8. Awards and Accolades
      • 5.3.1.9. Future Outlook
    • 5.3.2. Baxter BioPharma Solutions
      • 5.3.2.1. Company Overview
      • 5.3.2.2. Services Portfolio
      • 5.3.2.3. Financial Information
      • 5.3.2.4. Manufacturing Facilities
      • 5.3.2.5. Partnerships
      • 5.3.2.6. Recent Developments
      • 5.3.2.7. Awards and Accolades
      • 5.3.2.8. Future Outlook
    • 5.3.3. Catalent Biologics (Catalent Pharma Solutions)
      • 5.3.3.1. Company Overview
      • 5.3.3.2. Services Portfolio
      • 5.3.3.3. Financial Information
      • 5.3.3.4. Manufacturing Facilities
      • 5.3.3.5. Partnerships
      • 5.3.3.6. Recent Developments
      • 5.3.3.7. Awards and Accolades
      • 5.3.3.8. Future Outlook
    • 5.3.4. Cytovance Biologics
      • 5.3.4.1. Company Overview
      • 5.3.4.2. Services Portfolio
      • 5.3.4.3. Partnerships
      • 5.3.4.4. Recent Developments
      • 5.3.4.5. Awards and Accolades
      • 5.3.4.6. Future Outlook
    • 5.3.5. Patheon
      • 5.3.5.1 Company Overview
      • 5.3.5.2. Services Portfolio
      • 5.3.5.3. Financial Information
      • 5.3.5.4. Manufacturing Facilities
      • 5.3.5.5. Partnerships
      • 5.3.5.6. Recent Developments
      • 5.3.5.7. Awards and Accolades
      • 5.3.5.8. Future Outlook
    • 7.3.6. Piramal Pharma Solutions
      • 7.3.6.1. Company Overview
      • 7.3.6.2. Services Portfolio
      • 7.3.6.3. Financial Information
      • 7.3.6.4. Facilities
      • 7.3.6.5. Partnerships
      • 7.3.6.6. Recent Developments
      • 7.3.6.7. Future Outlook

6. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN EUROPE

  • 6.1. Chapter Overview
  • 6.2. Biopharmaceutical Outsourcing in Europe: Regulatory Scenario
  • 6.3. Leading Biopharmaceutical CMOs in Europe
    • 6.3.1. 3P Biopharmaceuticals
      • 6.3.1.1. Company Overview
      • 6.3.1.2. Services Portfolio
      • 6.3.1.3. Manufacturing Facilities
      • 6.3.1.4. Partnerships
      • 6.3.1.5. Recent Developments
      • 6.3.1.6. Future Outlook
    • 6.3.2. Boehringer Ingelheim BioXcellence&trade
      • 6.3.2.1. Company Overview
      • 6.3.2.2. Services Portfolio
      • 6.3.2.3. Financial Information
      • 6.3.2.4. Manufacturing Facilities
      • 6.3.2.5. Partnerships
      • 6.3.2.6. Recent Developments
      • 6.3.2.7. Future Outlook
    • 6.3.3. Celonic
      • 6.3.3.1. Company Overview
      • 6.3.3.2. Services Portfolio
      • 6.3.3.3. Manufacturing Facilities
      • 6.3.3.4. Partnerships
      • 6.3.3.5. Recent Developments
      • 6.3.3.6. Future Outlook
    • 6.3.4. FUJIFILM Diosynth Biotechnologies
      • 6.3.4.1. Company Overview
      • 6.3.4.2. Services Portfolio
      • 6.3.4.3. Financial Information
      • 6.3.4.4. Manufacturing Capabilities
      • 6.3.4.5. Partnerships
      • 6.3.4.6. Recent Developments
      • 6.3.4.7. Future Outlook
    • 6.3.5. LFB Group
      • 6.3.5.1. Company Overview
      • 6.3.5.2. Services Portfolio
      • 6.3.5.3. Financial Information
      • 6.3.5.4. Manufacturing Facilities
      • 6.3.5.5. Partnerships
      • 6.3.5.6. Recent Developments
      • 6.3.5.7. Future Outlook
    • 6.3.6. Lonza
      • 6.3.6.1. Company Overview
      • 6.3.6.2. Services Portfolio
      • 6.3.6.3. Financial Information
      • 6.3.6.4. Manufacturing Facilities
      • 6.3.6.5. Partnerships
      • 6.3.6.6. Recent Developments
      • 6.3.6.7. Future Outlook
    • 6.3.7. Menarini Biotech
      • 6.3.7.1. Company Overview
      • 6.3.7.2. Services Portfolio
      • 6.3.7.3. Partnerships
      • 6.3.7.4. Future Outlook
    • 6.3.8. Novasep
      • 6.3.8.1. Company Overview
      • 6.3.8.2. Services Portfolio
      • 6.3.8.3. Financial Information
      • 6.3.8.4. Partnerships
      • 6.3.8.5. Recent Developments
      • 6.3.8.6. Future Outlook
    • 6.3.9. Rentschler BioPharma
      • 6.3.9.1. Company Overview
      • 6.3.9.2. Services Portfolio
      • 6.3.9.3. Manufacturing Facilities
      • 6.3.9.4. Partnerships
      • 6.3.9.5. Recent Developments
      • 6.3.9.6. Future Outlook

7. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN ASIA PACIFIC AND THE REST OF THE WORLD

  • 7.1. Chapter Overview
  • 7.2. Biopharmaceutical Contract Manufacturing in China
    • 7.2.1. Biopharmaceutical Outsourcing in China: Regulatory Scenario
  • 7.3. Biopharmaceutical CMOs in China
    • 7.3.1. AutekBio
      • 7.3.1.1. Company Overview
      • 7.3.1.2. Services Portfolio
      • 7.3.1.3. Manufacturing Facilities
      • 7.3.1.4. Future Outlook
    • 7.3.2. WuXi AppTec (WuXi Biologics)
      • 7.3.2.1. Company Overview
      • 7.3.2.2. Services Portfolio
      • 7.3.2.3. Financial Information
      • 7.3.2.4. Manufacturing Facilities
      • 7.3.2.5. Partnerships
      • 7.3.2.6. Recent Developments
  • 7.4. Biopharmaceutical Contract Manufacturing in India
    • 7.4.1. Biopharmaceutical Outsourcing in India: Regulatory Scenario
  • 7.5. Biopharmaceutical CMOs in India
    • 7.5.1. Intas Pharmaceuticals
      • 7.5.1.1. Company Overview
      • 7.5.1.2. Services Portfolio
      • 7.5.1.3. Financial Information
      • 7.5.1.4. Manufacturing Facilities
      • 7.5.1.5. Partnerships
      • 7.5.1.6. Future Outlook
    • 7.5.2. Kemwell Biopharma
      • 7.5.2.1. Company Overview
      • 7.5.2.2. Services Portfolio
      • 7.5.2.3. Manufacturing Facilities
      • 7.5.2.4. Partnerships
      • 7.5.2.5. Recent Developments
      • 7.5.2.6. Future Outlook
    • 7.5.4. Shasun Pharmaceuticals
      • 7.5.4.1. Company Overview
      • 7.5.4.2. Services Portfolio
      • 7.5.4.3. Financial Information
      • 7.5.4.4. Future Outlook
    • 7.5.5. Syngene
      • 7.5.5.1. Company Overview
      • 7.5.5.2. Services Portfolio
      • 7.5.5.3. Financial Information
      • 7.5.5.4. Manufacturing Facilities
      • 7.5.5.5. Partnerships
      • 7.5.5.6. Recent Developments
      • 7.5.5.7. Future Outlook
  • 7.6. Biopharmaceutical Contract Manufacturing in Japan
    • 7.6.1. Biopharmaceutical Outsourcing in Japan: Regulatory Scenario
  • 7.7. Biopharmaceutical CMOs in Japan
    • 7.7.1. Asahi Glass
      • 7.7.1.1. Company Overview
      • 7.7.1.2. Services Portfolio
      • 7.7.1.3. Financial Information
      • 7.7.1.4. Manufacturing Facilities
      • 7.7.1.5. Partnerships
      • 7.7.1.6. Recent Developments
      • 7.7.1.7. Future Outlook
  • 7.8. Biopharmaceutical Contract Manufacturing in South Korea
    • 7.8.1. Biopharmaceutical Outsourcing in South Korea: Regulatory Scenario
  • 7.9. Biopharmaceutical CMOs in South Korea
    • 7.9.1. DM Bio
      • 7.9.1.1. Company Overview
      • 7.9.1.2. Services Portfolio
      • 7.9.1.3. Manufacturing Facilities
      • 7.9.1.4. Recent Developments
      • 7.9.1.5. Future Outlook
    • 7.9.2. Samsung BioLogics
      • 7.9.2.1. Company Overview
      • 7.9.2.2. Services Portfolio
      • 7.9.2.3. Financial Information
      • 7.9.2.4. Manufacturing Facilities
      • 7.9.2.5. Partnerships
      • 7.9.2.6. Recent Developments
      • 7.9.2.7. Future Outlook
  • 7.10. Biopharmaceutical Contract Manufacturing in Australia
    • 7.10.1. Biopharmaceutical Outsourcing in Australia: Regulatory Scenario
  • 7.11. Biopharmaceutical CMOs in Australia
    • 7.11.1. Cell Therapies
      • 7.11.1.1. Company Overview
      • 7.11.1.2. Services Portfolio
      • 7.11.1.3. Manufacturing Facilities
      • 7.11.1.4. Partnerships
      • 7.11.1.5. Recent Developments
      • 7.11.1.6. Future Outlook
    • 7.11.2. Luina Bio
      • 7.11.2.1. Company Overview
      • 7.11.2.2. Services Portfolio
      • 7.11.2.3. Manufacturing Facilities
      • 7.11.2.4. Partnerships
      • 7.11.2.5. Future Outlook

8. NICHE BIOPHARMACEUTICAL SECTORS

  • 8.1. Chapter Overview
  • 8.2. Antibody Drug Conjugates
    • 8.2.1. Introduction
      • 8.2.1.1. Manufacturing Process
      • 8.2.1.2. Key Technologies and Technology Providers
    • 8.2.2. Pipeline Analysis
      • 8.2.2.1. ADC Pipeline: Marketed and Clinical Molecules
      • 8.2.2.2. ADC Pipeline: Preclinical and Discovery Stage Molecules
      • 8.2.2.3. ADC Manufacturing: Key Challenges
  • 8.3. Bispecific Antibodies
    • 8.3.1. Introduction
      • 8.3.1.1.The Bispecific Advantage
    • 8.3.2. Pipeline Analysis
    • 8.3.3. Bispecific Antibody Technology Providers
    • 8.3.4. Contract Manufacturing Scenario
  • 8.4. Cell Therapies
    • 8.4.1. Introduction
    • 8.4.2. Current Market Landscape
    • 8.4.3. Cell Therapy Manufacturing
    • 8.4.4. Cell Therapy Manufacturing Models
      • 8.4.4.1. Centralized Manufacturing Model
      • 8.4.4.2. Decentralized Manufacturing Model
    • 8.4.5. Cell Therapy Manufacturing: Key Challenges and Growth Drivers
    • 8.4.6. Important Factors for Cell Therapy Manufacturing
    • 8.4.7. Contract Manufacturing Scenario
      • 8.4.7.1. Contract Manufacturing Market Landscape
      • 8.4.7.2. Analysis by Type of Cells Manufactured
      • 8.4.7.3. Analysis by Scale of Operation
  • 8.5. Gene Therapy
    • 8.5.1. Introduction
    • 8.5.2. Gene Therapy: Pipeline Analysis
      • 8.5.2.1. Analysis by Phase of Development
      • 8.5.2.2. Analysis by Type of Vector
      • 8.5.2.3. Analysis by Therapeutic Area
    • 8.5.3. Contract Manufacturing Market Landscape
      • 8.5.3.1. Analysis by Location
      • 8.5.3.2. Analysis by Type of Viral Vector
      • 8.5.3.3. Analysis by Scale of Production
  • 8.6. Plasmid DNA
    • 8.6.1. Introduction
    • 8.6.2. Contract Manufacturing Market Landscape
    • 8.6.3. Analysis by Location of Manufacturing Facility
    • 8.6.4. Analysis by Scale of Production

9. CASE STUDY: OUTSOURCING OF BIOSIMILARS

  • 9.1. Chapter Overview
  • 9.2. Biosimilars: An Introduction
  • 9.3. Biosimilars: Development Stages
  • 9.4. Regulatory Requirements for Licensing Biosimilars
  • 9.5. Need for Outsourcing Biosimilar Development and Manufacturing
  • 9.6. Impact of Biosimilars on the Global Contract Manufacturing Market
    • 9.6.1. Region-wise Distribution of Biosimilar Development / Manufacturing Activity
  • 9.7. Challenges Associated with Outsourcing Biosimilars
  • 10. CASE STUDY: COMPARISON OF SMALL MOLECULE AND LARGE MOLECULE DRUGS / THERAPIES
  • 10.1. Chapter Overview
  • 10.2. Small Molecule and Large Molecule Drugs / Therapies
    • 10.2.1. Comparison of General Characteristics
    • 10.2.2. Comparison of Key Specifications
    • 10.2.3. Comparison of Manufacturing Processes
    • 10.2.4. Comparison of Key Manufacturing Challenges

11. CASE STUDY ON IN-HOUSE MANUFACTURING

  • 11.1. Chapter Overview
  • 11.2. In-House Manufacturing
    • 11.2.1. Benefits Associated with In-House Manufacturing
    • 11.2.2. Risks Associated with In-House Manufacturing
  • 11.3. Outsourcing in the Biomanufacturing Industry
    • 11.3.1. Types of Outsourcing Partners
  • 11.4. Manufacturing Approaches Used for Approved Biologics (2016-2018)
    • 11.4.1. Approved Biologics: Analysis by Size of Developer and Type of Manufacturing Approach
    • 11.4.2. Approved Biologics: Analysis by Size of Developer and Type of Biologic
  • 11.5. Choosing the Right Strategy: In-House Manufacturing versus Outsourcing

12. COLLABORATIONS

  • 12.1. Chapter Overview
  • 12.2. Partnership Models
  • 12.3. Biopharmaceutical Contract Manufacturing: List of Partnerships and Collaborations
    • 12.3.1. Analysis by Year of Partnership
    • 12.3.2. Analysis by Type of Partnership
      • 12.3.2.1. Year-Wise Trend of Product-based Agreements
      • 12.3.2.2. Year-Wise Trend of Process-based Agreements
      • 12.3.2.3. Year-Wise Trend of Licensing Agreements
      • 12.3.2.4. Year-Wise Trend of Co-service Agreements / Ventures
      • 12.3.2.5. Year-Wise Trend of R&D Agreements
      • 12.3.2.6. Year-Wise Trend of Out-sourcing Services Agreements
    • 12.3.3. Analysis by Focus Area
    • 12.3.4. Analysis by Type of Biologic
      • 12.3.4.1. Analysis by Type of Biologic and Type of Partnership Model
      • 12.3.4.2. Analysis of Cell Therapy-related Deals by Year and Type of Partnership Model
      • 12.3.4.3. Analysis of Monoclonal Antibody-related Deals Year and Type of Partnership Model
      • 12.3.4.4. Analysis of Vaccine-related Deals by Year and Type of Partnership Model
      • 12.3.4.5. Analysis of Protein-related Deals by Year and Type of Partnership Model
      • 12.3.4.6. Analysis of Antibody Drug Conjugate-related Deals by Year and Type of Partnership Model
      • 12.3.4.7. Analysis of Vector-related Deals by Year and Type of Partnership Model
      • 12.3.4.8. Analysis of Gene Therapy-related Deals by Year and Type of Partnership Model
      • 12.3.4.9. Analysis of Biosimilar-related Deals by Year and Type of Partnership Model
      • 12.3.4.10. Analysis of Other Biologic-related Deals by Type of Partnership Model
      • 12.3.4.11. Analysis by Type of Biologic and Geography
    • 12.3.5. Analysis by Therapeutic Area
    • 12.3.6. Analysis of Most Active Players by Number of Partnerships
    • 12.3.7. Regional Analysis
      • 12.3.7.1. Intercontinental and Intracontinental Agreements
  • 12.4. Biopharmaceutical Contract Manufacturing: Mergers and Acquisitions
    • 12.4.1. Cumulative Year-wise Trend
    • 12.4.2. Analysis by Type of Acquisition
    • 12.4.3. Regional Analysis
      • 12.4.3.1. Continent-wise Distribution
      • 12.4.3.2. Country-wise Distribution
      • 12.4.3.3. Intercontinental and Intracontinental Deals
    • 12.4.4. Analysis of Most Active Acquirers by Number of Acquisitions
    • 12.4.5. Analysis by Key Value Drivers
      • 12.4.5.1. Analysis by Key Value Drivers and Year of Acquisition
    • 12.4.6. Analysis by Type of Biologic
      • 12.5.6.1. Analysis by Type of Biologic and Key Value Drivers
    • 12.4.7 Key Acquisitions: Deal Multiples

13. RECENT DEVELOPMENTS

  • 13.1. Chapter Overview
  • 13.2. Biopharmaceutical Contract Manufacturing Market: Facility Expansions
    • 13.2.1. Cumulative Year-wise Distribution
    • 13.2.2. Analysis by Purpose of Facility Expansion
    • 13.2.3. Analysis by Type of Biologic
    • 13.2.4. Analysis by Location of Facility
    • 13.2.5. Regional Analysis
    • 13.2.6. Analysis by Region and Purpose
  • 13.3. Biopharmaceutical Contract Manufacturing Market: Funding Instances
  • 13.4. Technological Advancements
    • 13.4.1. Single Use Technology
    • 13.4.2. Process Analytical Technology
    • 13.4.3. Continuous Processing
    • 13.4.4. Quality by Design in Bio-processing

14. CAPACITY ANALYSIS

  • 14.1. Chapter Overview
  • 14.2. Assumptions and Methodology
  • 14.3. Biopharmaceutical Contract Manufacturers: Global Production Capacity
    • 14.3.1. Analysis by Region
    • 14.3.2. Analysis by Expression Systems
    • 14.3.3. Analysis by Scale of Operation
  • 14.4. ADC Contract Manufacturers: Global Production Capacity
  • 14.5. Cell Therapy Manufacturers: Production Capacity
  • 14.6. Vector Manufacturers: Production Capacity
  • 14.7. Concluding Remarks

15. DEMAND ANALYSIS

  • 15.1. Chapter Overview
  • 15.2. Key Assumptions and Methodology
  • 15.3. Biopharmaceutical Contract Manufacturing Market: Overall Annual Demand
    • 15.3.1. Analysis by Therapeutic Area
  • 15.4. ADCs: Overall Annual Demand
    • 15.4.1. ADCs: Demand and Supply Analysis

16. MARKET FORECAST

  • 16.1. Chapter Overview
  • 16.2. Forecast Methodology and Key Assumptions
  • 16.3. Overall Biopharmaceutical Contract Manufacturing Market, 2019-2030
    • 16.3.1. Biopharmaceutical Contract Manufacturing Market for API Manufacturing, 2019-2030
    • 16.3.2. Biopharmaceutical Contract Manufacturing Market for FDF Manufacturing, 2019-2030
  • 16.4. Biopharmaceutical Contract Manufacturing Market, 2019-2030: Distribution by Expression Systems Used
  • 16.5. Biopharmaceutical Contract Manufacturing Market, 2019-2030: Distribution by Scale of Operation
  • 16.6. Biopharmaceutical Contract Manufacturing Market, 2019-2030: Distribution by Size of Manufacturers
  • 16.7. Biopharmaceutical Contract Manufacturing Market, 2019-2030: Distribution by Geography
    • 16.7.1. Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030
      • 16.7.1.1. Biopharmaceutical Contract Manufacturing Market in the US, 2019-2030
      • 16.7.1.2. Biopharmaceutical Contract Manufacturing Market in Rest of North America, 2019-2030
      • 16.7.1.3. Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Mammalian Cell-based Operations
      • 16.7.1.4. Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Microbial Cell-based Operations
      • 16.7.1.5. Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Other Expression System-based Operations
      • 16.7.1.6. Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Preclinical / Clinical Scale Operations
      • 16.7.1.7. Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Commercial Operations
      • 16.7.1.8. Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Small-sized Companies
      • 16.7.1.9. Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Mid-sized Companies
      • 16.7.1.10. Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Large / Very Large Companies
    • 16.7.2. Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030
      • 16.7.2.1. Biopharmaceutical Contract Manufacturing Market in Italy, 2019-2030
      • 16.7.2.2. Biopharmaceutical Contract Manufacturing Market in Germany, 2019-2030
      • 16.7.2.3. Biopharmaceutical Contract Manufacturing Market in France, 2019-2030
      • 16.7.2.4. Biopharmaceutical Contract Manufacturing Market in Spain, 2019-2030
      • 16.7.2.5. Biopharmaceutical Contract Manufacturing Market in the UK, 2019-2030
      • 16.7.2.6. Biopharmaceutical Contract Manufacturing Market in Rest of Europe, 2019-2030
      • 16.7.2.7. Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Mammalian Cell-based Operations
      • 16.7.2.8. Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Microbial Cell-based Operations
      • 16.7.2.9. Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Other Expression System-based Operations
      • 16.7.2.10. Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Preclinical / Clinical Operations
      • 16.7.2.11. Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Commercial Operations
      • 16.7.1.12. Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Small-sized Companies
      • 16.7.1.13. Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Mid-sized Companies
      • 16.7.1.14. Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Large / Very Large Companies
    • 16.7.2. Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030
      • 16.7.2.1. Biopharmaceutical Contract Manufacturing Market in China, 2019-2030
      • 16.7.2.2. Biopharmaceutical Contract Manufacturing Market in India, 2019-2030
      • 16.7.2.3. Biopharmaceutical Contract Manufacturing Market in South Korea, 2019-2030
      • 16.7.2.4. Biopharmaceutical Contract Manufacturing Market in Japan, 2019-2030
      • 16.7.2.5. Biopharmaceutical Contract Manufacturing Market in Australia, 2019-2030
      • 16.7.2.6. Biopharmaceutical Contract Manufacturing Market in Rest of Asia and Other Regions, 2019-2030
      • 16.7.2.7. Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Mammalian Cell-based Operations
      • 16.7.2.8. Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Microbial Cell-based Operations
      • 16.7.2.9. Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Other Expression System-based Operations
      • 16.7.2.10. Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Preclinical / Clinical Operations
      • 16.7.2.11. Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Commercial Operations
      • 16.7.1.12. Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Small-sized Companies
      • 16.7.1.13. Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Mid-sized Companies
      • 16.7.1.14. Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Large / Very Large Companies

17. SWOT ANALYSIS

  • 17.1 Chapter Overview
  • 17.2. Strengths
  • 17.3. Weaknesses
  • 17.4. Opportunities
  • 17.5. Threats
  • 17.6. Comparison of Swot Factors
  • 17.7. Concluding Remarks

18. FUTURE OF THE BIOPHARMACEUTICAL CMO MARKET

  • 18.1. Chapter Overview
  • 18.2. Outsourcing Activities to Witness Significant Growth in the Coming Years
  • 18.3. Shift from One-time Contracts to Strategic Partnerships
  • 18.4. Integration / Adoption of New and Innovative Technologies
    • 18.4.1. Single use Bioreactors
    • 18.4.2. Novel Bioprocess Techniques
    • 18.4.3. Bioprocess Automation
  • 18.5. Focus on Niche Therapeutic Areas
  • 18.6. Growing Biosimilars Market to Contribute to the Growth of the Contract Services Segment
  • 18.7. Capability and Expertise Expansions by CMOs to become One Stop Shops
  • 18.8. Offshoring Outsourcing Activities to Maximize Profits and Expand Existing Capacities
  • 18.9. Increase in Financial Inflow and Outsourcing Budgets
  • 18.10. The Need for Humanized Products to Drive the Growth of Mammalian Expression Technologies
  • 18.11. Challenges Faced by both Sponsors and Service Providers
    • 18.11.1. Concerns related to Single Use Systems
    • 18.11.2. Issues Related to Capacity Fluctuations
  • 18.12. Concluding Remarks

19. SURVEY ANALYSIS

  • 19.1. Chapter Overview
    • 19.1.1. Overview of Respondents
    • 19.1.2. Designation of Respondents
  • 19.2. Biologics Manufacturing Expertise
  • 19.3. Scale of Manufacturing
  • 19.4. Location of Production Facilities
  • 19.5. Types of Expression Systems Used
  • 19.6. Types of Bioreactors
  • 19.7. Modes of Operation of Bioreactors

20. INTERVIEW TRANSCRIPTS

  • 20.1. Chapter Overview
  • 20.2. Astrid Brammer, Senior Manager Business Development, Richter-Helm
  • 20.3. Birgit Schwab, Senior Manager Strategic Marketing, Rentschler Biotechnologie
  • 20.4. Christian Bailly, Director of CDMO, Pierre Fabre
  • 20.5. Claire Otjes, Assistant Marketing Manager, Batavia Biosciences
  • 20.6. David C Cunningham, Director Corporate Development, Goodwin Biotechnology
  • 20.7. Dietmar Katinger, Chief Executive Officer, Polymun Scientific
  • 20.8. Denis Angioletti, Chief Commercial Officer, Cerbios-Pharma
  • 20.9. Jeffrey Hung, Chief Commercial Officer, Vigene Biosciences
  • 20.10. Kevin Daley, Director Pharmaceuticals, Novasep
  • 20.11. Mark Wright, Site Head, Grangemouth, Piramal Healthcare
  • 20.12. Nicolas Grandchamp, R&D Leader, GEG Tech
  • 20.13. Raquel Fortunato, Chief Executive Officer, GenIbet Biopharmaceuticals
  • 20.14. Sebastian Schuck, Head of Business Development, Wacker Biotech
  • 20.15. Stephen Taylor, Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies
  • 20.16. Tatjana Buchholz, Marketing Manager, PlasmidFactory and Marco Schmeer, Project Manager, PlasmidFactory
  • 20.17. Tim Oldham, Chief Executive Officer, Cell Therapies
  • 21. APPENDIX 1: LIST OF NON-INDUSTRY PLAYERS
  • 22. APPENDIX 2: TABULATED DATA
  • 23. APPENDIX 3: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

  • Figure 3.1: Types of Biopharmaceuticals
  • Figure 3.2: Stages of the Biomanufacturing Process
  • Figure 3.3: Types of Third-Party Service Providers
  • Figure 3.4: Commonly Outsourced Business Operations
  • Figure 3.5: Key Factors to Consider while Selecting a CMO Partner
  • Figure 3.6: Risks and Challenges Associated with Contract Manufacturing
  • Figure 4.1: Biopharmaceutical CMOs: Distribution by Year of Establishment
  • Figure 4.2: Biopharmaceutical CMOs: Distribution by Size of Employee Base
  • Figure 4.3: Biopharmaceutical CMOs: Distribution by Location of Headquarters (Region-wise)
  • Figure 4.4: Biopharmaceutical CMOs: Distribution by Location of Headquarters (Country-wise)
  • Figure 4.5: Biopharmaceutical CMOs: Distribution by Location of Manufacturing Facility (Region-wise)
  • Figure 4.6: Biopharmaceutical CMOs: Distribution by Location of Manufacturing Facility (Country-wise)
  • Figure 4.7: Biopharmaceutical CMOs: Distribution by Types of Biologics Manufactured
  • Figure 4.8: Biopharmaceutical CMOs: Distribution by Scale of Operation
  • Figure 4.9: Biopharmaceutical CMOs: Distribution by Types of Expression Systems Used
  • Figure 5.10: Biopharmaceutical Industry: The US Market Scenario
  • Figure 5.2: Biopharmaceutical Contract Manufacturing in the US: Growth Drivers and Challenges
  • Figure 5.3: US FDA Guidelines: Elements of a Quality Agreement
  • Figure 5.4: US FDA Guidelines: Key Considerations for Biologic Manufacturing Operations
  • Figure 5.5: Common Manufacturing Operations Offered by CMOs
  • Figure 5.6: AMRI: Service Portfolio
  • Figure 5.7: AMRI: Annual Revenues (USD Million)
  • Figure 5.8: AMRI: Revenues by Business Divisions (USD Million)
  • Figure 5.9: Baxter BioPharma Solutions: Customized Support Services Portfolio
  • Figure 5.10: Baxter BioPharma Solutions: ADCs Related Services
  • Figure 5.11: Baxter BioPharma Solutions: Regulatory Services
  • Figure 5.12: Baxter International: Annual Revenues (USD Billion)
  • Figure 5.13: Catalent: Biologics Services Portfolio
  • Figure 5.14: Catalent: Biosimilars Services Portfolio
  • Figure 5.15: Catalent: Annual Revenues (USD Million)
  • Figure 5.16: Catalent: Annual Revenues by Business Divisions (USD Million)
  • Figure 5.17: Cytovance: Services Portfolio
  • Figure 5.18: Patheon: Services Portfolio
  • Figure 5.19: Patheon: Services and Solutions for Biologics
  • Figure 5.20: Patheon: Services and Solutions for Small Molecules
  • Figure 5.21: Patheon: Annual Revenues (USD Million)
  • Figure 5.22: Patheon: Revenues by Business Segments (USD Million)
  • Figure 5.23: Piramal Pharma Solutions: Annual Revenues (USD Million)
  • Figure 6.1: Biopharmaceutical Contract Manufacturing in Europe: Growth Drivers and Challenges
  • Figure 6.2: EMA GMP Guidelines: Key Considerations of the Contract Giver, Contract Acceptor and the Contract
  • Figure 6.3: LFB Group: Services Portfolio
  • Figure 6.4: LFB Biomanufacturing Services: Services Portfolio
  • Figure 6.5: LFB Group: Annual Revenues (EUR Million)
  • Figure 6.6: LFB Group: Revenues by Therapeutic Area and Services (EUR Million)
  • Figure 6.7: Menarini Biotech: Services Portfolio
  • Figure 6.8: Novasep: Products Portfolio
  • Figure 6.9: Novasep: Annual Revenues (EUR Million)
  • Figure 6.10: Rentschler Biopharma: Services Portfolio
  • Figure 6.11: Boehringer Ingelheim BioXcellence&trade: Services Portfolio
  • Figure 6.12: Boehringer Ingelheim: Annual Revenues (EUR Billion)
  • Figure 6.13: Boehringer Ingelheim: Revenues by Business Divisions (EUR Billion)
  • Figure 6.14: Celonic: Services Portfolio
  • Figure 6.15: Lonza: Services Portfolio
  • Figure 6.16: Lonza: Annual Revenues (CHF Billion)
  • Figure 6.17: FUJIFILM Diosynth Biotechnologies: Services Portfolio
  • Figure 6.18: FUJIFILM Diosynth Biotechnologies: Annual Revenues (JPY Billion)
  • Figure 6.19: FUJIFILM Holdings: Annual Revenues by Business Divisions (JPY Billion)
  • Figure 6.20: 3P Biopharmaceuticals: Services Portfolio
  • Figure 7.1: Biopharmaceutical Contract Manufacturing in China: Growth Drivers
  • Figure 7.2: Biopharmaceutical Contract Manufacturing in China: Challenges
  • Figure 7.3: Chinese Regulatory Guidelines: Key Considerations of the Contract Giver
  • Figure 7.4: Chinese Regulatory Guidelines: Key Considerations of the Contract Acceptor
  • Figure 7.5: Chinese Regulatory Guidelines: Key Aspects of the Contract
  • Figure 7.6: Autotek Bio: Services Portfolio
  • Figure 7.7: Autotek Bio: DisposUp Technology
  • Figure 7.8: WuXi Biologics: Services Portfolio
  • Figure 7.9: WuXi Biologics: Antibody Discovery Procedure
  • Figure 7.10: Wuxi Biologics: Annual Revenues (RMB Million)
  • Figure 7.11: Wuxi Biologics: Annual Revenues by Regions of Operation (RMB million)
  • Figure 7.12: Biopharmaceutical Contract Manufacturing in India: Growth Drivers
  • Figure 7.13: Biopharmaceutical Contract Manufacturing in India: Challenges
  • Figure 7.14: Intas Pharmaceuticals: Annual Revenues (INR Million)
  • Figure 7.15: Strides Shasun: Annual Revenues (INR Million)
  • Figure 7.16: Syngene: Services Portfolio
  • Figure 7.17: Syngene: Annual Revenues (INR Million)
  • Figure 7.18: Asahi Glass: Services Portfolio
  • Figure 7.19: Asahi Glass: Annual Revenues (JPY Million)
  • Figure 7.20: DM Bio: Services Portfolio
  • Figure 7.21: DM Bio: Manufacturing Services
  • Figure 7.22: Samsung BioLogics: Services Portfolio
  • Figure 7.23: Samsung BioLogics: Annual Revenues from CMO Operations (KRW Billion)
  • Figure 7.24: Cell Therapies: Services Portfolio
  • Figure 7.25: LuinaBio: Services Portfolio
  • Figure 8.1: ADCs: Structure
  • Figure 8.2: ADCs Pipeline: Distribution by Phase of Development
  • Figure 8.3: Bispecific Antibody: Structure
  • Figure 8.4: Bispecific Antibody Pipeline: Distribution by Phase of Development
  • Figure 8.5: Steps for Manufacturing Cell Therapies
  • Figure 8.6: Centralized Manufacturing: Process Model
  • Figure 8.7: Decentralized Manufacturing: Process Model
  • Figure 8.8: Cell Therapy: Challenges and Drivers
  • Figure 8.9: Cell Therapy: Critical Quality Attribute (Potency)
  • Figure 8.10: Gene Therapy, Clinical and Preclinical Pipeline: Distribution by Phase of Development
  • Figure 8.11: Gene Therapy, Clinical Pipeline: Distribution by Vector Types
  • Figure 8.12: Gene Therapy, Preclinical Pipeline: Distribution by Vector Types
  • Figure 8.13: Gene Therapy, Clinical Pipeline: Distribution by Therapeutic Area
  • Figure 8.14: Gene Therapy CMOs: Distribution by Region
  • Figure 8.15: Viral Vectors Manufacturers: Distribution by Type of Viral Vector
  • Figure 8.16: Viral Vectors Manufacturers: Distribution by Scale of Production
  • Figure 8.17: Plasmid DNA Manufacturers: Distribution by Location of Manufacturing Facility
  • Figure 8.18: Plasmid DNA Manufacturers: Distribution by Scale of Production
  • Figure 9.1: Biosimilars: Stages of Manufacturing
  • Figure 9.2: Biosimilars: Analytical and Functional Characterization Methods for Key Product Attributes
  • Figure 9.3: Regulatory Process for Licensing of a Biosimilar Product
  • Figure 9.4: Need for Outsourcing Biosimilar Manufacturing
  • Figure 9.5: Biosimilars Pipeline: Country-wise Distribution
  • Figure 9.6: Challenges Associated with Biosimilar Outsourcing
  • Figure 10.1: Small Molecule and Large Molecule Drugs: Historical Trend of FDA Approval (2005 - November 2018)
  • Figure 10.2: Small Molecules and Large Molecules: Comparison of Key Characteristics
  • Figure 10.3: Small Molecules and Large Molecules: Comparison of Manufacturing Process
  • Figure 11.1: Benefits Associated with In-House Manufacturing
  • Figure 11.2: Risks Associated with In-House Manufacturing
  • Figure 11.3: Advantages and Disadvantages of Different Types of Outsourcing Partnerships
  • Figure 11.4: Approved Biologics: Distribution by Size of Developer and Type of Manufacturing Model
  • Figure 11.5: Approved Biologics: Distribution by Size of Developer and Type of Biologic
  • Figure 12.1: Collaborations: Cumulative Trend by Year, 2013- 2018
  • Figure 12.2: Collaborations: Distribution by Type of Partnership Model
  • Figure 12.3: Collaborations: Cumulative Year-wise Trend of Product-based Agreements, 2013 - 2018
  • Figure 12.4: Collaborations: Cumulative Year-wise Trend of Process-based Agreements, 2013 - 2018
  • Figure 12.5: Collaborations: Cumulative Year-wise Trend of Licensing Agreements, 2013 - 2018
  • Figure 12.6: Collaborations: Cumulative Year-wise Trend of Co-Service Agreements / Ventures, 2013 - 2018
  • Figure 12.7: Collaborations: Cumulative Year-wise Trend of R&D Agreements, 2013 - 2018
  • Figure 12.8: Collaborations: Cumulative Year-wise Trend of Outsourcing Services Agreements, 2013 - 2018
  • Figure 12.9: Collaborations: Distribution by Focus Area
  • Figure 12.10: Collaborations: Distribution by Focus Area and Type of Partnership Model
  • Figure 12.11: Collaborations: Distribution by Type of Biologic
  • Figure 12.12: Collaborations: Distribution by Type of Biologic and Type of Partnership Model
  • Figure 12.13: Collaborations: Distribution of Cell Therapy-related Deals by Year and Type of Partnership Model
  • Figure 12.14: Collaborations: Distribution of Monoclonal Antibody-related Deals by Year and Type of Partnership Model
  • Figure 12.15: Collaborations: Distribution of Vaccine-related Deals by Year and Type of Partnership Model
  • Figure 12.16: Collaborations: Distribution of Protein-related Deals by Year and Type of Partnership Model
  • Figure 12.17: Collaborations: Distribution of Antibody Drug Conjugate-related Deals by Year and Type of Partnership Model
  • Figure 12.18: Collaborations: Distribution of Vector-related Deals by Year and Type of Partnership Model
  • Figure 12.19: Collaborations: Distribution of Gene Therapy-related Deals by Year and Type of Partnership Model
  • Figure 12.20: Collaborations: Distribution of Biosimilar-related Deals by Year and Type of Partnership Model
  • Figure 12.21: Collaborations: Distribution of Other Biologic-related Deals by Type of Partnership Model
  • Figure 12.22: Collaborations: Distribution of Manufacturing Agreements by Type of Biologic and Geography
  • Figure 12.23: Collaborations: Distribution by Therapeutic Area
  • Figure 12.24: Collaborations: Most Active Players
  • Figure 12.25: Collaborations: Regional Distribution
  • Figure 12.26: Collaborations: Intercontinental and Intracontinental Distribution
  • Figure 12.27: Mergers and Acquisitions: Year-Wise Cumulative Trend (2013- 2018)
  • Figure 12.28: Mergers and Acquisitions: Distribution by Type of Acquisition
  • Figure 12.29: Mergers and Acquisitions: Continent-wise Distribution
  • Figure 12.30: Mergers and Acquisitions: Country-wise Distribution
  • Figure 12.31: Mergers and Acquisitions: Intercontinental and Intracontinental Acquisitions
  • Figure 12.32: Mergers and Acquisitions: Most Active Acquirers
  • Figure 12.33: Mergers and Acquisitions: Key Value Drivers
  • Figure 12.34: Mergers and Acquisitions: Distribution by Key Value Drivers and Year of Acquisition
  • Figure 12.35: Mergers and Acquisitions: Distribution by Type of Biologic
  • Figure 12.36: Mergers and Acquisitions: Heat Map Analysis
  • Figure 12.37: Mergers and Acquisitions: Relationship between Important Deal Multiples
  • Figure 13.1: Facility Expansions: Cumulative Year-wise Trend, 2013-2018
  • Figure 13.2: Facility Expansions: Distribution by Purpose
  • Figure 13.3: Facility Expansions: Distribution by Type of Biologic
  • Figure 13.4: Facility Expansions: Distribution by Location of Facility (Region-wise)
  • Figure 13.5: Facility Expansions: Distribution by Location of Headquarters (Country-wise)
  • Figure 13.6: Facility Expansions: Regional Distribution
  • Figure 13.7: Facility Expansions: Distribution by Region and Purpose
  • Figure 14.1: Capacity Analysis: Global Contract Biomanufacturing Capacity by Size of Employee Base of Contract Manufacturers
  • Figure 14.2: Capacity Analysis: Regional Distribution of Biopharmaceutical CMOs
  • Figure 14.3: Capacity Analysis: Regional Production Capacity of Biopharmaceutical CMOs
  • Figure 14.4: Capacity Analysis: Regional Contract Biomanufacturing Capacity
  • Figure 14.5: Capacity Analysis: Percentage Distribution of Contract Biomanufacturing Capacity by Expression Systems Used
  • Figure 14.6: Capacity Analysis: Distribution by Scale of Operation
  • Figure 14.7: Geographical Distribution of ADC Manufacturing Capacity
  • Figure 14.8: Geographical Distribution of Cell Therapy Manufacturing Capacity
  • Figure 14.9: Geographical Distribution of Vector Manufacturing Capacity
  • Figure 15.1: Demand Analysis: Annual Demand for Biopharmaceuticals (in Kilograms)
  • Figure 15.2: Demand Analysis: Annual Demand for ADCs (in Kilograms)
  • Figure 16.1: Overall Biopharmaceutical Contract Manufacturing Market, 2019-2030
  • Figure 16.2: Biopharmaceutical Contract Manufacturing Market for API Manufacturing, 2019-2030 (USD Billion)
  • Figure 16.3: Biopharmaceutical Contract Manufacturing Market for FDF Manufacturing, 2019-2030 (USD Billion)
  • Figure 16.4: Biopharmaceutical Contract Manufacturing Market, 2019-2030: Distribution by Expression Systems Used (USD Billion)
  • Figure 16.5: Biopharmaceutical Contract Manufacturing Market, 2019-2030: Distribution by Scale of Operation (USD Billion)
  • Figure 16.6: Biopharmaceutical Contract Manufacturing Market, 2019-2030: Distribution by Size of Employee Base of Contract Manufacturers (USD Billion)
  • Figure 16.7: Biopharmaceutical Contract Manufacturing Market, 2019-2030: Distribution by Geography (USD Billion)
  • Figure 16.8: Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030 (USD Billion)
  • Figure 16.9: Biopharmaceutical Contract Manufacturing Market in the US, 2019-2030 (USD Billion)
  • Figure 16.10: Biopharmaceutical Contract Manufacturing Market in Rest of North America, 2019-2030 (USD Billion)
  • Figure 16.11: Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Mammalian Cell-based Operations (USD Billion)
  • Figure 16.12: Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Microbial Cell-based Operations (USD Billion)
  • Figure 16.13: Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Other Expression System-based Operations (USD Billion)
  • Figure 16.14: Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Preclinical / Clinical Scale Operations (USD Billion)
  • Figure 16.15: Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Commercial Operations (USD Billion)
  • Figure 16.16: Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Small-sized Companies (USD Billion)
  • Figure 16.17: Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Mid-sized Companies (USD Billion)
  • Figure 16.18: Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Large / Very Large Companies (USD Billion)
  • Figure 16.19: Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030 (USD Billion)
  • Figure 16.20: Biopharmaceutical Contract Manufacturing Market in Italy, 2019-2030 (USD Billion)
  • Figure 16.21: Biopharmaceutical Contract Manufacturing Market in Germany, 2019-2030 (USD Billion)
  • Figure 16.22: Biopharmaceutical Contract Manufacturing Market in France, 2019-2030 (USD Billion)
  • Figure 16.23: Biopharmaceutical Contract Manufacturing Market in Spain, 2019-2030 (USD Billion)
  • Figure 16.24: Biopharmaceutical Contract Manufacturing Market in the UK, 2019-2030 (USD Billion)
  • Figure 16.25: Biopharmaceutical Contract Manufacturing Market in Rest of Europe, 2019-2030 (USD Billion)
  • Figure 16.26: Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Mammalian Cell-based Operations (USD Billion)
  • Figure 16.27: Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Microbial Cell-based Operations (USD Billion)
  • Figure 16.28: Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Other Expression System-based Operations (USD Billion)
  • Figure 16.29: Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Preclinical / Clinical Operations (USD Billion)
  • Figure 16.30: Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Commercial Operations (USD Billion)
  • Figure 16.31: Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Small-sized Companies (USD Billion)
  • Figure 16.32: Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Mid-sized Companies (USD Billion)
  • Figure 16.33: Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Large / Very Large Companies (USD Billion)
  • Figure 16.34: Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030 (USD Billion)
  • Figure 16.35: Biopharmaceutical Contract Manufacturing Market in China, 2019-2030 (USD Billion)
  • Figure 16.36: Biopharmaceutical Contract Manufacturing Market in India, 2019-2030 (USD Billion)
  • Figure 16.37: Biopharmaceutical Contract Manufacturing Market in South Korea, 2019-2030 (USD Billion)
  • Figure 16.38: Biopharmaceutical Contract Manufacturing Market in Japan, 2019-2030 (USD Billion)
  • Figure 16.39: Biopharmaceutical Contract Manufacturing Market in Australia, 2019-2030 (USD Billion)
  • Figure 16.40: Biopharmaceutical Contract Manufacturing Market in Rest of Asia and Other Regions, 2019-2030 (USD Billion)
  • Figure 16.41: Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Mammalian Cell-based Operations (USD Billion)
  • Figure 16.42: Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Microbial Cell-based Operations (USD Billion)
  • Figure 16.43: Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Other Expression System-based Operations (USD Billion)
  • Figure 16.44: Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Preclinical / Clinical Operations (USD Billion)
  • Figure 16.45: Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Commercial Operations (USD Billion)
  • Figure 16.46: Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Small-sized Companies (USD Billion)
  • Figure 16.47: Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Mid-sized Companies (USD Billion)
  • Figure 16.48: Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Large / Very Large Companies (USD Billion)
  • Figure 17.1: Biopharmaceutical Contract Manufacturing: SWOT Analysis
  • Figure 17.2: Global Biopharmaceuticals Market: Number of FDA Approvals by Year, 2002-2018
  • Figure 17.3: Comparison of SWOT Factors: Harvey Ball Analysis
  • Figure 19.1: Survey Analysis: Distribution of Respondents by Company Type
  • Figure 19.2: Survey Analysis: Distribution of Respondents by Location of Headquarters
  • Figure 19.3: Survey Analysis: Distribution of Respondents by Designation
  • Figure 19.4: Survey Analysis: Distribution by Biologics Manufacturing Expertise
  • Figure 19.5: Survey Analysis: Distribution by Scale of Manufacturing
  • Figure 19.6: Survey Analysis: Distribution by Location of Production Facilities
  • Figure 19.7: Survey Analysis: Distribution by Types of Expression Systems Used
  • Figure 19.8: Survey Analysis: Distribution by Types of Bioreactors
  • Figure 19.9: Survey Analysis: Distribution by Modes of Operation of Bioreactors

List of Tables

  • Table 4.1: List of Biopharmaceutical CMOs
  • Table 4.2: Biopharmaceutical CMOs: Information on Types of Biologics Manufactured
  • Table 4.3: Biopharmaceutical CMOs: Information on Scale of Operation
  • Table 4.4: Biopharmaceutical CMOs: Information on Types of Expression Systems Used
  • Table 4.5: Biopharmaceutical CMOs: Information on Types of Bioreactors
  • Table 4.6: Biopharmaceutical CMOs: Information on Mode of Operation of Bioreactor
  • Table 4.7: Biopharmaceutical CMOs: Information on Biomanufacturing Capacity
  • Table 4.8: Biopharmaceutical CMOs: Information on Type of Packaging Forms
  • Table 5.1: AMRI (OsoBio): Company Overview
  • Table 5.2: AMRI (OsoBio): Partnerships and Collaborations
  • Table 5.3: AMRI (OsoBio): Future Outlook
  • Table 5.4: Baxter Bio Pharma Solutions: Company Overview
  • Table 5.5: Baxter BioPharma Solutions: Partnerships
  • Table 5.6: Baxter BioPharma Solutions: Future Outlook
  • Table 5.7: Catalent Biologics: Company Overview
  • Table 5.8: Catalent Biologics: Facilities
  • Table 5.9: Catalent Biologics: Partnerships
  • Table 5.10: Catalent Biologics: Future Outlook
  • Table 5.11: Cytovance: Company Overview
  • Table 5.12: Cytovance: Partnerships
  • Table 5.13: Cytovance: Future Outlook
  • Table 5.14: Patheon: Company Overview
  • Table 5.15: Patheon: Biopharmaceutical Manufacturing and Development Facilities
  • Table 5.16: Patheon: Partnerships
  • Table 5.17: Patheon: Future Outlook
  • Table 5.18: Piramal Pharma Solutions: Company Overview
  • Table 5.19: Piramal Pharma Solutions: Facilities
  • Table 5.20: Piramal Pharma Solutions: Partnerships
  • Table 5.21: Piramal Pharma Solutions: Future Outlook
  • Table 6.1: FDA Quality Agreement and EMA cGMP Regulations: A Comparative Analysis
  • Table 6.2: LFB Group: Company Overview
  • Table 6.3: LFB Biomanufacturing: Partnerships
  • Table 6.4: LFB Biomanufacturing: Future Outlook
  • Table 6.5: Menarini Biotech: Company Overview
  • Table 6.6: Menarini Biotech: Partnerships
  • Table 6.7: Menarini Biotech: Future Outlook
  • Table 6.8: Novasep: Company Overview
  • Table 6.9: Novasep: Partnerships
  • Table 6.10: Novasep: Future Outlook
  • Table 6.11: Rentschler Biopharma: Company Overview
  • Table 6.12: Rentschler Biopharma: Partnerships
  • Table 6.13: Rentschler Biopharma: Future Outlook
  • Table 6.14: Boehringer Ingelheim: Company Overview
  • Table 6.15: Boehringer Ingelheim BioXcellence&trade: Biopharmaceutical Facilities
  • Table 6.16: Boehringer Ingelheim BioXcellence&trade: Partnerships
  • Table 6.17: Boehringer Ingelheim BioXcellence&trade: Future Outlook
  • Table 6.18: Celonic: Company Overview
  • Table 6.19: Celonic: Biopharmaceutical Facilities
  • Table 6.20: Celonic: Partnerships
  • Table 6.21: Celonic: Future Outlook
  • Table 6.22: Lonza: Company Overview
  • Table 6.23: Lonza: Biopharmaceutical Facilities
  • Table 6.24: Lonza: Partnerships
  • Table 6.24: Lonza: Future Outlook
  • Table 6.25: FUJIFILM Diosynth Biotechnologies: Company Overview
  • Table 6.26: FUJIFILM Diosynth Biotechnologies: Partnerships
  • Table 6.27: FUJIFILM Diosynth Biotechnologies: Future Outlook
  • Table 6.28: 3P Biopharmaceuticals: Company Overview
  • Table 6.29: 3P Biopharmaceuticals: Partnerships
  • Table 6.30: 3P Biopharmaceuticals: Future Outlook
  • Table 7.1: AutekBio: Company Overview
  • Table 7.1: AutekBio: Future Outlook
  • Table 7.2: WuXi AppTec (WuXi Biologics): Company Overview
  • Table 7.3: Wuxi Biologics: Partnerships
  • Table 7.4: Wuxi Biologics: Future Outlook
  • Table 7.5: Intas Pharmaceuticals: Company Overview
  • Table 7.6: Intas Pharmaceuticals: Other Facilities
  • Table 7.7: Intas Pharmaceuticals: Partnerships
  • Table 7.8: Intas Pharmaceuticals: Future Outlook
  • Table 7.9: Kemwell Biopharma: Company Overview
  • Table 7.10: Kemwell Biopharma: Partnerships
  • Table 7.11: Kemwell Biopharma: Future Outlook
  • Table 7.12: Shashun Pharmaceuticals: Company Overview
  • Table 7.13: Syngene Pharmaceuticals: Company Overview
  • Table 7.14: Syngene: Partnerships
  • Table 7.15: Syngene: Future Outlook
  • Table 7.16: AGC Biologics: Company Overview
  • Table 7.17: AGC Biologics: Partnerships
  • Table 7.18: AGC Biologics: Future Outlook
  • Table 7.19: DM Bio: Company Overview
  • Table 7.20: DM Bio: Future Outlook
  • Table 7.21: Samsung BioLogics: Company Overview
  • Table 7.22: Samsung BioLogics: Biopharmaceutical Facilities
  • Table 7.23: Samsung BioLogics: Partnerships
  • Table 7.24: Samsung BioLogics: Future Outlook
  • Table 7.25: Cell Therapies: Company Overview
  • Table 7.26: Cell Therapies: Partnerships
  • Table 7.27: Cell Therapies: Future Outlook
  • Table 7.28: LuinaBio: Company Overview
  • Table 7.29: LuinaBio: Partnerships
  • Table 7.30: LuinaBio: Future Outlook
  • Table 8.1: ADC Pipeline: Marketed and Clinical Molecules
  • Table 8.2: ADC Pipeline: Preclinical and Discovery Stage Molecules
  • Table 8.3: Bispecific Antibody Pipeline: Clinical Stage Molecules
  • Table 8.4: Bispecific Antibody Pipeline: Preclinical and Discovery Stage Molecules
  • Table 8.5: Bispecific Antibody Technologies and Technology Providers
  • Table 8.6: Application of Cell-based Therapies
  • Table 8.7: Commercialized Products for Cell-based Therapies
  • Table 8.8: Assessment Strategies for Different Manufacturing Processes
  • Table 8.9: Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
  • Table 8.10: List of Cell Therapy Contract Manufacturers
  • Table 8.11: Cell Therapy Contract Manufacturers: Information on Type of Cell Therapy
  • Table 8.12: Cell Therapy Contract Manufacturers: Information on Scale of Operation
  • Table 8.13: List of Viral Vector Manufacturers
  • Table 8.14: Viral Vector Manufacturers: Information on Type of Viral Vectors
  • Table 8.15: List of Plasmid DNA Manufacturers
  • Table 10.1: Small Molecules and Large Molecules: Strengths and Weaknesses
  • Table 10.2: Small Molecules and Large Molecules: Comparison of Development Characteristics
  • Table 11.1: List of FDA Approved Biologics (2016-2018)
  • Table 12.1: Biopharmaceutical Contract Manufacturing: List of Collaborations, 2013 - 2018
  • Table 12.2: Biopharmaceutical Contract Manufacturing Collaborations: Information on Types of Biologics)
  • Table 12.3: Biopharmaceutical Contract Manufacturing: List of Mergers and Acquisitions, 2013 - 2018
  • Table 12.4: Biopharmaceutical Contract Manufacturing Mergers and Acquisitions: Information on Key Value Drivers
  • Table 12.5: Mergers and Acquisitions: Important Deal Multiples, 2013- 2018
  • Table 13.1: Biopharmaceutical Contract Manufacturing: Recent Developments
  • Table 13.2: Biopharmaceutical Contract Manufacturing: Funding Instances
  • Table 14.1: Capacity Analysis: CMO Size Adjustments based on Capacity
  • Table 14.2: Capacity Analysis: CMO Size Adjustments based on Size of Employee Base
  • Table 14.3: Capacity Analysis: Key Assumptions and Inputs
  • Table 14.4: Capacity Analysis: Global Contract Biomanufacturing Capacity
  • Table 14.4: Capacity Analysis: Regional Contract Biomanufacturing Capacity
  • Table 17.1: Global Biopharmaceuticals Market: Patent Information of Best-selling Biologics
  • Table 19.1: Survey Analysis: Overview of Respondents
  • Table 19.2: Survey Analysis: Distribution of Respondents by Designation
  • Table 19.3: Survey Analysis: Biologics Manufacturing Expertise
  • Table 19.4: Survey Analysis: Scale of Manufacturing
  • Table 19.5: Survey Analysis: Location of Production Facilities
  • Table 19.6: Survey Analysis: Type of Expression Systems Used
  • Table 19.7: Survey Analysis: Type of Bioreactors
  • Table 19.8: Survey Analysis: Mode of Operation of Bioreactors
  • Table 22.1: Biopharmaceutical CMOs: Distribution by Year of Establishment
  • Table 22.2: Biopharmaceutical CMOs: Distribution by Size of Employee Base
  • Table 22.3: Biopharmaceutical CMOs: Distribution by Location of Headquarters (Region-wise)
  • Table 22.4: Biopharmaceutical CMOs: Distribution by Location of Headquarters (Country-wise)
  • Table 22.5: Biopharmaceutical CMOs: Distribution by Location of Manufacturing Facility (Region-wise)
  • Table 22.6: Biopharmaceutical CMOs: Distribution by Location of Manufacturing Facility (Country-wise)
  • Table 22.7: Biopharmaceutical CMOs: Distribution by Types of Biologic
  • Table 22.8: Biopharmaceutical CMOs: Distribution by Scale of Operation
  • Table 22.9: Biopharmaceutical CMOs: Distribution by Types of Expression Systems Used
  • Table 22.10: AMRI: Annual Revenues (USD Million)
  • Table 22.11: Baxter International: Annual Revenues (USD Billion)
  • Table 22.12: Catalent: Annual Revenues (USD Million)
  • Table 22.13: Catalent: Annual Revenues by Business Divisions (USD Million)
  • Table 22.14: Patheon: Annual Revenues (USD Million)
  • Table 22.15: Patheon: Revenues by Business Segments USD Million)
  • Table 22.16: Piramal Pharma Solutions: Annual Revenues (USD Million)
  • Table 22.17: LFB Group: Annual Revenues (EUR Million)
  • Table 22.18: LFB Group: Revenues by Therapeutic Area and Services (EUR Million)
  • Table 22.19: Novasep: Annual Revenues (EUR Million)
  • Table 22.20: Boehringer Ingelheim: Annual Revenues (USD Billion)
  • Table 22.21: Boehringer Ingelheim: Revenues by Business Divisions (EUR Billion)
  • Table 22.22: Lonza: Annual Revenues (CHF Billion)
  • Table 22.23: FUJIFILM Diosynth Biotechnologies: Annual Revenues (JPY Billion)
  • Table 22.24: FUJIFILM Holdings: Annual Revenues by Business Divisions (JPY Billion)
  • Table 22.25: Wuxi Biologics: Annual Revenues (RMB Million)
  • Table 22.26: Wuxi Biologics: Annual Revenues by Regions of Operation (RMB million)
  • Table 22.27: Intas Pharmaceuticals: Annual Revenues (INR Million)
  • Table 22.28: Strides Shasun: Annual Revenues (INR Million)
  • Table 22.29: Syngene: Annual Revenues (INR Million)
  • Table 22.30: Asahi Glass: Annual Revenues (JPY Million)
  • Table 22.31: Samsung BioLogics: Annual Revenues from CMO Operations (KRW Billion)
  • Table 22.32: Bispecific Antibody: Distribution by Phase of Development
  • Table 22.33: Gene Therapy, Clinical and Preclinical Pipeline: Distribution by Phase of Development
  • Table 22.34: Gene Therapy, Clinical Pipeline: Distribution by Vector Type
  • Table 22.35: Gene Therapy, Preclinical Pipeline: Distribution by Vector Type
  • Table 22.36: Gene Therapy, Clinical Pipeline: Distribution by Therapeutic Area
  • Table 22.37: Gene Therapy CMOs: Distribution by Region
  • Table 22.38: Viral Vectors Manufacturers: Distribution by Type of Viral Vector
  • Table 22.39: Viral Vectors Manufacturers: Distribution by Scale of Production
  • Table 22.40: Plasmid DNA Manufacturers: Distribution by Location of Manufacturing Facility
  • Table 22.41: Plasmid DNA Manufacturers: Distribution by Scale of Production
  • Table 22.42: Biosimilars Pipeline: Country-wise Distribution
  • Table 22.43: Small Molecule and Large Molecule Drugs: Historical Trend of FDA Approval (2005 - November 2018)
  • Table 22.44: Approved Biologics: Distribution by Size of Developer and Type of Manufacturing Model
  • Table 22.45: Approved Biologics: Distribution by Size of Developer and Type of Biologic
  • Table 22.46: Collaborations: Cumulative Trend by Year, 2013-November 2018
  • Table 22.47: Collaborations: Distribution by Type of Partnership Model
  • Table 22.48: Collaborations: Cumulative Year-wise Trend of Product-based Agreements, 2013 - 2018
  • Table 22.49: Collaborations: Cumulative Year-wise Trend of Process-based Agreements, 2013 - 2018
  • Table 22.50: Collaborations: Cumulative Year-wise Trend of Licensing Agreements, 2013 - 2018
  • Table 22.51: Collaborations: Cumulative Year-wise Trend of Co-Service Agreements / Ventures, 2013 - 2018
  • Table 22.52: Collaborations: Cumulative Year-wise Trend of R&D Agreements, 2013 - 2018
  • Table 22.53: Collaborations: Cumulative Year-wise Trend of Outsourcing Services Agreements, 2013 - 2018
  • Table 22.54: Collaborations: Distribution by Focus Area
  • Table 22.55: Collaborations: Distribution by Focus Area and Type of Partnership Model
  • Table 22.56: Collaborations: Distribution by Type of Biologic
  • Table 22.57: Collaborations: Distribution by Type of Biologic and Type of Partnership Model
  • Table 22.58: Collaborations: Distribution of Cell Therapy-related Deals by Year and Type of Partnership Model
  • Table 22.59: Collaborations: Distribution of Monoclonal Antibody-related Deals by Year and Type of Partnership Model
  • Table 22.60: Collaborations: Distribution of Vaccine-related Deals by Year and Type of Partnership Model
  • Table 22.61: Collaborations: Distribution of Proteins-related Deals by Year and Type of Partnership Model
  • Table 22.62: Collaborations: Distribution of Antibody Drug Conjugate-related Deals by Year and Type of Partnership Model
  • Table 22.63: Collaborations: Distribution of Vector-related Deals by Year and Type of Partnership Model
  • Table 22.64: Collaborations: Distribution of Gene Therapy-related Deals by Year and Type of Partnership Model
  • Table 22.65: Collaborations: Distribution of Biosimilar-related Deals by Year and Type of Partnership Model
  • Table 22.66: Collaborations: Distribution of Other Biologic-related Deals by Type of Partnership Model
  • Table 22.67: Collaborations: Distribution of Manufacturing Agreements by Type of Biologic and Geography
  • Table 22.68: Collaborations: Distribution by Therapeutic Area
  • Table 22.69: Collaborations: Most Active Players
  • Table 22.70: Collaborations: Regional Distribution
  • Table 22.71: Collaborations: Intercontinental and Intracontinental Distribution
  • Table 22.72: Mergers and Acquisitions: Year-Wise Cumulative Trend, 2013- 2018
  • Table 22.73: Mergers and Acquisitions: Distribution by Type of Acquisitions
  • Table 22.74: Mergers and Acquisitions: Continental Distribution
  • Table 22.75: Mergers and Acquisitions: Country-wise Distribution
  • Table 22.76: Mergers and Acquisitions: Intercontinental and Intracontinental Acquisitions
  • Table 22.77: Mergers and Acquisitions: Most Active Acquirers
  • Table 22.78: Mergers and Acquisitions: Distribution by Key Value Drivers and Year of Acquisition
  • Table 22.79: Mergers and Acquisitions: Distribution by Type of Biologics
  • Table 22.80: Deal Multiples Analysis: Relationship between Deal Multiples for Revenue and Number of Employees
  • Table 22.81: Facility Expansions: Cumulative Year-wise Trend, 2013-2018
  • Table 22.82: Facility Expansions: Distribution by Purpose
  • Table 22.83: Facility Expansions: Distribution by Type of Biologic
  • Table 22.84: Facility Expansions: Distribution by Location of Facility (Region-wise)
  • Table 22.85: Facility Expansions: Distribution by Location of Headquarters (Country-wise)
  • Table 22.86: Facility Expansions: Regional Distribution
  • Table 22.87: Facility Expansions: Distribution by Region and Purpose
  • Table 22.88: Capacity Analysis: Global Contract Biomanufacturing Capacity by Size of Employee Base of Contract Manufacturers
  • Table 22.89: Capacity Analysis: Regional Distribution of Biopharmaceutical CMOs
  • Table 22.90: Capacity Analysis: Regional Production Capacity of Biopharmaceutical CMOs
  • Table 22.91: Capacity Analysis: Regional Contract Biomanufacturing Capacity
  • Table 22.92: Capacity Analysis: Distribution by Expression Systems Used
  • Table 22.93: Capacity Analysis: Distribution by Scale of Operation
  • Table 22.94: Geographical Distribution of ADC Manufacturing Capacity
  • Table 22.95: Geographical Distribution of Cell Therapy Manufacturing Capacity
  • Table 22.96: Geographical Distribution of Vector Manufacturing Capacity
  • Table 22.97: Overall Biopharmaceutical Contract Manufacturing Market, 2019-2030 (USD Billion)
  • Table 22.98: Biopharmaceutical Contract Manufacturing Market for API Manufacturing, 2019-2030 (USD Billion)
  • Table 22.99: Biopharmaceutical Contract Manufacturing Market for FDF Manufacturing, 2019-2030 (USD Billion)
  • Table 22.100: Biopharmaceutical Contract Manufacturing Market, 2019-2030: Distribution by Expression Systems Used (USD Billion)
  • Table 22.101: Biopharmaceutical Contract Manufacturing Market, 2019-2030: Distribution by Scale of Operation (USD Billion)
  • Table 22.102: Biopharmaceutical Contract Manufacturing Market, 2019-2030: Distribution by Size of Employee Base of Contract Manufacturers (USD Billion)
  • Table 22.103: Biopharmaceutical Contract Manufacturing Market, 2019-2030: Distribution by Geography (USD Billion)
  • Table 22.104: Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030 (USD Billion)
  • Table 22.105: Biopharmaceutical Contract Manufacturing Market in the US, 2019-2030 (USD Billion)
  • Table 22.106: Biopharmaceutical Contract Manufacturing Market in Rest of North America, 2019-2030 (USD Billion)
  • Table 22.107: Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: for Share of Mammalian Cell-based Operations (USD Billion)
  • Table 22.108: Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Microbial Cell-based Operations (USD Billion)
  • Table 22.109: Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Other Expression System-based Operations (USD Billion)
  • Table 22.110: Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Preclinical / Clinical Scale Operations (USD Billion)
  • Table 22.111: Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Commercial Operations (USD Billion)
  • Table 22.112: Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Small-sized Companies (USD Billion)
  • Table 22.113: Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Mid-sized Companies (USD Billion)
  • Table 22.114: Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Large / Very Large Companies (USD Billion)
  • Table 22.115: Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030 (USD Billion)
  • Table 22.116: Biopharmaceutical Contract Manufacturing Market in Italy, 2019-2030 (USD Billion)
  • Table 22.117: Biopharmaceutical Contract Manufacturing Market in Germany, 2019-2030 (USD Billion)
  • Table 22.118: Biopharmaceutical Contract Manufacturing Market in France, 2019-2030 (USD Billion)
  • Table 22.119: Biopharmaceutical Contract Manufacturing Market in Spain, 2019-2030 (USD Billion)
  • Table 22.120: Biopharmaceutical Contract Manufacturing Market in the UK, 2019-2030 (USD Billion)
  • Table 22.121: Biopharmaceutical Contract Manufacturing Market in Rest of Europe, 2019-2030 (USD Billion)
  • Table 22.122: Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Mammalian Cell-based Operations (USD Billion)
  • Table 22.123: Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Microbial Cell-based Operations (USD Billion)
  • Table 22.124: Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Other Expression System-based Operations (USD Billion)
  • Table 22.125: Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Preclinical / Clinical Operations (USD Billion)
  • Table 22.126: Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Commercial Operations (USD Billion)
  • Table 22.127: Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Small-sized Companies (USD Billion)
  • Table 22.128: Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Mid-sized Companies (USD Billion)
  • Table 22.129: Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Large / Very Large Companies (USD Billion)
  • Table 22.130: Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030 (USD Billion)
  • Table 22.131: Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030 (USD Billion)
  • Table 22.132: Biopharmaceutical Contract Manufacturing Market in China, 2019-2030 (USD Billion)
  • Table 22.133: Biopharmaceutical Contract Manufacturing Market in India, 2019-2030 (USD Billion)
  • Table 22.134: Biopharmaceutical Contract Manufacturing Market in South Korea, 2019-2030 (USD Billion)
  • Table 22.135: Biopharmaceutical Contract Manufacturing Market in Japan, 2019-2030 (USD Billion)
  • Table 22.136: Biopharmaceutical Contract Manufacturing Market in Australia, 2019-2030 (USD Billion)
  • Table 22.137: Biopharmaceutical Contract Manufacturing Market in Rest of Asia and Other Regions, 2019-2030 (USD Billion)
  • Table 22.138: Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Mammalian Cell-based Operations (USD Billion)
  • Table 22.139: Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Microbial Cell-based Operations (USD Billion)
  • Table 22.140: Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Other Expression System-based Operations (USD Billion)
  • Table 22.141: Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Preclinical / Clinical Operations (USD Billion)
  • Table 22.142: Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Commercial Operations (USD Billion)
  • Table 22.143: Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Small-sized Companies (USD Billion)
  • Table 22.144: Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Mid-sized Companies (USD Billion)
  • Table 22.145: Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Large / Very Large Companies (USD Billion)
  • Table 22.146: Survey Analysis: Distribution of Respondents by Company Type
  • Table 22.147: Survey Analysis: Distribution of Respondents by Location of Headquarters
  • Table 22.148: Survey Analysis: Distribution of Respondents by Designation
  • Table 22.149: Survey Analysis: Distribution by Biologics Manufacturing Expertise
  • Table 22.150: Survey Analysis: Distribution by Scale of Manufacturing
  • Table 22.151: Survey Analysis: Distribution by Location of Production Facility
  • Table 22.152: Survey Analysis: Distribution by Type of Expression System Used
  • Table 22.153: Survey Analysis: Distribution by Type of Bioreactor
  • Table 22.154: Survey Analysis: Distribution by Mode of Operation of Bioreactor

Listed Companies

  • 1. 3P Biopharmaceuticals
  • 2. Aalto Scientific
  • 3. AbbVie Contract Manufacturing
  • 4. Abeona Therapeutics
  • 5. Abzena
  • 6. ACES Pharma
  • 7. Adar Biotech
  • 8. ADC Biotechnology
  • 9. Adimmune
  • 10. Advanced BioScience Laboratories
  • 11. Advent Bioservices
  • 12. Affinity Life Sciences
  • 13. Afton Scientific
  • 14. AGC Biologics
  • 15. Ajinomoto Bio-Pharma
  • 16. Akdeniz University
  • 17. Alberta Cell Therapy Manufacturing
  • 18. Alcami
  • 19. Aldevron
  • 20. Allele Biotechnology & Pharmaceuticals
  • 21. Almac
  • 22. Alnylam Pharmaceuticals
  • 23. Amatsigroup
  • 24. AmbioPharm
  • 25. AMEGA Biotech
  • 26. Amgen
  • 27. Andalusian Initiative for Advanced Therapies
  • 28. Anogen-Yes Biotech Laboratories
  • 29. apceth Biopharma
  • 30. Arabio
  • 31. AstraZeneca
  • 32. Asymchem Laboratories
  • 33. Atlantic Bio GMP
  • 34. AURA Biotechnologies
  • 35. Austrianova
  • 36. AutekBio
  • 37. Avecia
  • 38. Avid Bioservices
  • 39. Axcellerate Pharma
  • 40. Baccinex
  • 41. Bachem
  • 42. Batavia Biosciences
  • 43. Baxter BioPharma Solutions
  • 44. Bayer
  • 45. Baylor College of Medicine
  • 46. BCN Peptides
  • 47. Bharat Serums and Vaccines
  • 48. BIBITEC
  • 49. BINEX
  • 50. Bio Elpida
  • 51. BioCell
  • 52. BIOFABRI
  • 53. Biogen
  • 54. Bioinova
  • 55. BioInvent International
  • 56. Biological E.
  • 57. BioMARC
  • 58. BioMarin
  • 59. Biomay
  • 60. BioNTech IMFS
  • 61. Biopolis
  • 62. BioReliance
  • 63. Biosynergy (Europe)
  • 64. Bio-Synthesis
  • 65. BioTechnique
  • 66. Biotechpharma
  • 67. BioVectra
  • 68. Biovian
  • 69. Boehringer Ingelheim BioXcellence
  • 70. Boston Institute of Biotechnology
  • 71. Brammer Bio
  • 72. Bryllan
  • 73. BSP Pharmaceuticals
  • 74. Burrard Pharmaceuticals
  • 75. C3i Solutions
  • 76. Canada Peptide
  • 77. Capua BioServices
  • 78. CARBOGEN AMCIS
  • 79. Case Western Reserve University
  • 80. Catalent Biologics
  • 81. CCGTT Centre, Royal Free Hospital
  • 82. Cell and Gene Therapy Catapult
  • 83. Cell Culture Company
  • 84. Cell Essentials
  • 85. Cell Tech Pharmed
  • 86. Cell Therapies
  • 87. Cell Therapy Manufacturing CRC
  • 88. Cellin Technologies
  • 89. Celltrion
  • 90. Cellular Therapeutics
  • 91. Celonic
  • 92. Cenexi
  • 93. Center of Excellence for Cellular Therapy
  • 94. Centre for Cell and Vector Production
  • 95. Century Pharmaceuticals
  • 96. Cerbios-Pharma
  • 97. Charles River Laboratories
  • 98. Chemi Peptides
  • 99. ChemPartner
  • 100. Children's Hospital of Philadelphia
  • 101. CinnaGen
  • 102. City of Hope
  • 103. Clinical Cell and Vaccine Production Facility
  • 104. Cobra Biologics
  • 105. Cognate BioServices
  • 106. Cook MyoSite
  • 107. CordenPharma
  • 108. Cornell University
  • 109. Creative Biolabs
  • 110. CRMI
  • 111. Cryosite
  • 112. CSIRO
  • 113. CSL Behring
  • 114. Cytovance Biologics
  • 115. Dalton Pharma Services
  • 116. DM Bio
  • 117. Dompé
  • 118. Duke University
  • 119. Dynavax Technologies
  • 120. EirGenix
  • 121. Eli Lilly
  • 122. Elusys Therapeutics
  • 123. EMD Serono
  • 124. Emergent BioSolutions
  • 125. Emory University School of Medicine
  • 126. EuBiologics
  • 127. EUCODIS Bioscience
  • 128. EVER Pharma
  • 129. Exelead
  • 130. FinVector Vision Therapies
  • 131. Foundation for Biomedical Research and Innovation
  • 132. Fraunhofer Insitute for Cell Therapy and Immunology
  • 133. Fresenius Kabi Contract Manufacturing
  • 134. FUJIFILM Diosynth Biotechnologies
  • 135. Gates Biomanufactuirng Facility
  • 136. GC Cell
  • 137. GenCure (subsidiary of BioBridge Global)
  • 138. Gene Therapy Laboratory of Nantes
  • 139. Gene Transfer Vector Core
  • 140. GeneCure Biotechnologies
  • 141. GenIbet Biopharmaceuticals
  • 142. GlaxoSmithKline
  • 143. Glenmark
  • 144. Goodwin Biotechnology
  • 145. GP Pharm
  • 146. Grand River Aseptic Manufacturing
  • 147. GreenPak Biotech
  • 148. Grifols
  • 149. GTP Technology
  • 150. Guy's and St Thomas' Facility
  • 151. HALIX
  • 152. Harvard Gene Therapy Initiative
  • 153. Health Biotech
  • 154. Health Sciences Authority
  • 155. Hetero Drugs
  • 156. Histocell
  • 157. Hisun Pharmaceuticals USA
  • 158. Hong Kong Institute of Biotechnology
  • 159. Hycult Biotech
  • 160. IDT Biologika
  • 161. IncoCell Tianjin
  • 162. Indian Immunologicals
  • 163. Indiana University
  • 164. Inno Biologics
  • 165. Institute of Medical Science Research
  • 166. Institute of Translational Health Sciences
  • 167. Integrity Bio
  • 168. Islet and Cellular Transplant Facility, University of California
  • 169. Istituto Biochimico Italiano Giovanni Lorenzini
  • 170. Janssen Pharmaceuticals
  • 171. Japan Tissue Engineering
  • 172. Jazz Pharmaceuticals
  • 173. Jenner Institute
  • 174. JHL Biotech
  • 175. John Goldman Centre for Cellular Therapy
  • 176. Jubilant HollisterStier
  • 177. Julphar Gulf Pharmaceutical Industries
  • 178. KABS Pharmaceutical Services
  • 179. Kamada
  • 180. Kamat PharmaTech
  • 181. Kaneka Eurogentec (previously known as Eurogentec, now a part of Kaneka)
  • 182. KBI Biopharma
  • 183. Kemwell Biopharma
  • 184. King's College London
  • 185. Kite Pharma
  • 186. KUBio (a manufacturing unit of GE Healthcare)
  • 187. Kyowa Hakko Kirin
  • 188. LAMPIRE Biological Laboratories
  • 189. LEUKOCARE
  • 190. Leuven Viral Vector Core
  • 191. Levena Biopharma
  • 192. LFB BIOMANUFACTURING
  • 193. Lonza
  • 194. Loughborough University
  • 195. LSNE Contract Manufacturing
  • 196. LuinaBio
  • 197. Lyophilization Technology
  • 198. Mabion
  • 199. MabPlex
  • 200. Mab-Venture Biopharma
  • 201. Maine Biotechnology Services
  • 202. Massachusetts Institute of Technology
  • 203. MassBiologics
  • 204. MaSTherCell
  • 205. Mayo Clinic Cancer Center
  • 206. McMaster University
  • 207. MEDINET
  • 208. Medix Biochemica
  • 209. MedStar Georgetown University Hospital
  • 210. Memorial Sloan Kettering Cancer Center
  • 211. Menarini Biotech
  • 212. Merck
  • 213. Meridian Life Science
  • 214. MGH Vector Core
  • 215. MicroBiopharm Japan
  • 216. Miller School of Medicine, University of Miami
  • 217. Miltenyi Biotec
  • 218. Moffitt Cancer Center
  • 219. MolMed
  • 220. Morphotek
  • 221. MuseChem
  • 222. Mycenax Biotech
  • 223. Mylan
  • 224. National Eye Institute (NEI)
  • 225. National Institute of Neurodegenerative Disorders and Stroke Center Core, University of Minnesota
  • 226. National University of Ireland, Galway
  • 227. Nationwide Children's Hospital
  • 228. Netherlands Cancer Institute (NKI)
  • 229. Neuland Laboratories
  • 230. NeuroCure (Viral Core Facility)
  • 231. NHS Blood and Transplant Service (NHSBT)
  • 232. Nikon CeLL innovation
  • 233. Nitto Avecia Pharma Services
  • 234. Norwegian Institute of Public Health
  • 235. Novartis
  • 236. Novasep
  • 237. Novex Innovations
  • 238. Novo Nordisk
  • 239. Octapharma
  • 240. OctoPlus (a part of Dr. Reddy's)
  • 241. Olon
  • 242. oncomed manufacturing
  • 243. Oncotec Pharma Produktion
  • 244. OsoBio
  • 245. Oxford BioMedica
  • 246. Panacea Biotec
  • 247. Paragon Bioservices
  • 248. Particle Sciences (A Lubrizol Company)
  • 249. Patheon
  • 250. PaxVax
  • 251. PCI (Biotec Services International)
  • 252. PCT (a subsidiary of Hitachi Chemical)
  • 253. Pfizer
  • 254. Pharmedartis
  • 255. Pharmicell
  • 256. Pierre Fabre
  • 257. Piramal Pharma Solutions
  • 258. PlasmidFactory
  • 259. Polpharma Biologics
  • 260. Polymun Scientific
  • 261. PolyPeptide Group
  • 262. Porton Biopharma
  • 263. Praxis Pharmaceutical
  • 264. Precision Antibody
  • 265. PREMAS Biotech
  • 266. PrimaPharma
  • 267. Princess Margaret Hospital
  • 268. ProBioGen
  • 269. Profectus BioSciences
  • 270. ProMab Biotechnologies
  • 271. Protein Sciences
  • 272. Provia Labs
  • 273. PX'Therapeutics
  • 274. PYRAMID Laboratories
  • 275. QIMR Berghofer Medical Research Institute
  • 276. Regeneron
  • 277. Rentschler Biotechnologie
  • 278. Richter-Helm BioLogics
  • 279. Riyadh Pharma
  • 280. Roche
  • 281. Rommelag CMO
  • 282. RoslinCT
  • 283. Roswell Park Cancer Institute
  • 284. Salk Institute for Biological Studies
  • 285. Samsung BioLogics
  • 286. Sandoz
  • 287. Sanford Burnham Prebys Medical Discovery Institute
  • 288. Sanofi
  • 289. Sanquin
  • 290. Sarepta Therapeutics
  • 291. Scientific Protein Laboratories
  • 292. Scil Proteins
  • 293. Seattle Children's Hospital
  • 294. Senn Chemicals
  • 295. Shire
  • 296. Siam Bioscience
  • 297. Sicor Biotech
  • 298. Siegfried
  • 299. Sigma-Aldrich Fine Chemicals (SAFC)
  • 300. SignaGen Laboratories
  • 301. Singota Solutions
  • 302. SNBTS Cellular Therapy Development Centre
  • 303. South London and Maudsley NHS Foundation Trust
  • 304. Spark Therapeutics
  • 305. ST Pharm
  • 306. St. Jude Children's Research Hospital
  • 307. Stanford University
  • 308. Stem Cell Institute (MediStem Panama)
  • 309. Swissfillon
  • 310. Sydney Cell and Gene Therapy
  • 311. Symbiosis Pharmaceutical Services
  • 312. SynCo Bio Partners
  • 313. Syngene (a subsidiary of Biocon)
  • 314. Synthelis
  • 315. Synthon
  • 316. Sypharma
  • 317. TaiMed Biologics
  • 318. Takara Bio
  • 319. Tanvex BioPharma
  • 320. TBD-Biodiscovery
  • 321. Telethon Institute of Genetics and Medicine
  • 322. Teva Pharmaceutical Industries
  • 323. The Centre for Stem Cell Research
  • 324. The Goldyne Savad Institute of Gene Therapy, Hadassah Medical Organization
  • 325. The Native Antigen Company
  • 326. The Ottawa Hospital Research Institute
  • 327. Therapure Biopharma
  • 328. Toyobo Biologics
  • 329. TranXenoGen
  • 330. Trenzyme
  • 331. UAB Vector Production Facility
  • 332. Ultragenyx Pharmaceutical
  • 333. UMC Utrecht
  • 334. University College London
  • 335. University Hospital Basel
  • 336. University of Barcelona
  • 337. University of Birmingham
  • 338. University of Califonia
  • 339. University of Florida
  • 340. University of Iowa
  • 341. University of Manchester
  • 342. University of Massachusetts Medical School (UMMS)
  • 343. University of Michigan Medical Center
  • 344. University of Nebraska
  • 345. University of Newcastle
  • 346. University of North Carolina
  • 347. University of Oxford
  • 348. University of Pennsylvania
  • 349. University of Pittsburgh
  • 350. University of Rochester
  • 351. University of South Carolina School of Medicine
  • 352. University of Texas
  • 353. University of Utah
  • 354. USC School of Pharmacy
  • 355. Valeant Pharmaceuticals
  • 356. Vecura (Karolinska University Hospital )
  • 357. Vetter Pharma
  • 358. VGXI
  • 359. Vibalogics
  • 360. Vigene Biosciences
  • 361. Viral Vector Facility (VVF), Neuroscience Center Zurich (ZNZ)
  • 362. Virovek
  • 363. WACKER Biotech
  • 364. Waisman Biomanufacturing
  • 365. Washington University School of Medicine
  • 366. WuXi AppTec
  • 367. Wuxi Griffin Pharmaceutical
  • 368. Xellbiogene
  • 369. Yale School of Medicine
  • 370. YposKesi
Back to Top